GEN Exclusives

More »

GEN News Highlights

More »
May 13, 2014

KBI Biopharma Gains Biomanufacturing Facility in Colorado

  • KBI Biopharma signed an agreement with Merck to acquire Merck’s microbial process development and manufacturing operations in Boulder, Colorado. Effective May 1, 2014, KBI will provide ongoing development and manufacturing services to Merck, as well as to third-party customers.

    “KBI will now offer expanded microbial development and manufacturing services up to 1,500 L scale, as well as continuing to offer our current full range of process development, analytical, and formulation development and mammalian manufacturing services up to 2,000 L,” said Joe McMahon, president and CEO of KBI. KBI will also continue to support other ongoing drug development programs for Merck from its two North Carolina facilities.

    According to McMahon, KBI has helped to advance more than 220 molecules in 55 different health indications for over 170 clients around the world.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »